Published September 30, 2024 | Version http://impactfactor.org/PDF/IJTPR/14/IJTPR,Vol14,Issue9,Article13.pdf
Journal article Open

A Comparative Evaluation of the Efficacy of Oral Terbinafine versus Itraconazole in the Treatment of Dermatophytosis

Authors/Creators

  • 1. Associate Professor, Department of Pharmacology, Kakatiya Medical College and Hospital, Warangal, Telangana
  • 2. Associate Professor, Department of Pharmacology, Government Medical College, Mahabubabad, Telangana

Description

Background: Dermatophytic infections, often worsened by hot and humid climates, are common fungal infections. Terbinafine and itraconazole are widely used oral antifungal agents to treat these conditions. However, increasing resistance to these drugs at conventional doses and durations has been observed. Consequently, this study was designed to compare the efficacy of terbinafine and itraconazole when administered in treating tinea corporis and tinea cruris. Methods: A randomized, prospective comparative study was conducted, involving 80 newly diagnosed patients with tinea corporis and tinea cruris, aged 18 years and above. The clinical diagnosis was confirmed using a potassium hydroxide (KOH) test. Patients were divided into two groups: Group I and Group II. Group I received oral itraconazole 100 mg twice daily, while Group II received oral terbinafine 250 mg twice daily, both treatments lasting for six weeks. Patients were followed up at the 2nd, 4th, and 6th weeks. Results: The mean age of patients of group I and group II cases was 38.19 ± 13.5 and 35.28 ±13.5 years respectively. Most cases (78.75%) involved both tinea corporis and tinea cruris, indicating a combined presentation. Tinea corporis was the second most common diagnosis, accounting for 10% of cases. Tinea cruris was the least common diagnosis, representing 11.25% of cases. Both groups experienced noticeable improvements in the presence of erythema. Group II showed significant improvement in scaling as compared to group I as shown by significant p values at the end of the second follow up and third follow up. The pruritus scores were substantially improved in group II indicating faster resolution. It appears that both medications are capable of improving clinical symptoms related to dermatophytosis. Conclusion: Both itraconazole and terbinafine are effective treatment options for the treatment of dermatophytosis. However, terbinafine appears to offer superior efficacy in addressing scaling and pruritus, especially in the early stages of treatment. The incidences of adverse drug reactions were low in both groups and both medications were well tolerated.

Abstract (English)

Background: Dermatophytic infections, often worsened by hot and humid climates, are common fungal infections. Terbinafine and itraconazole are widely used oral antifungal agents to treat these conditions. However, increasing resistance to these drugs at conventional doses and durations has been observed. Consequently, this study was designed to compare the efficacy of terbinafine and itraconazole when administered in treating tinea corporis and tinea cruris. Methods: A randomized, prospective comparative study was conducted, involving 80 newly diagnosed patients with tinea corporis and tinea cruris, aged 18 years and above. The clinical diagnosis was confirmed using a potassium hydroxide (KOH) test. Patients were divided into two groups: Group I and Group II. Group I received oral itraconazole 100 mg twice daily, while Group II received oral terbinafine 250 mg twice daily, both treatments lasting for six weeks. Patients were followed up at the 2nd, 4th, and 6th weeks. Results: The mean age of patients of group I and group II cases was 38.19 ± 13.5 and 35.28 ±13.5 years respectively. Most cases (78.75%) involved both tinea corporis and tinea cruris, indicating a combined presentation. Tinea corporis was the second most common diagnosis, accounting for 10% of cases. Tinea cruris was the least common diagnosis, representing 11.25% of cases. Both groups experienced noticeable improvements in the presence of erythema. Group II showed significant improvement in scaling as compared to group I as shown by significant p values at the end of the second follow up and third follow up. The pruritus scores were substantially improved in group II indicating faster resolution. It appears that both medications are capable of improving clinical symptoms related to dermatophytosis. Conclusion: Both itraconazole and terbinafine are effective treatment options for the treatment of dermatophytosis. However, terbinafine appears to offer superior efficacy in addressing scaling and pruritus, especially in the early stages of treatment. The incidences of adverse drug reactions were low in both groups and both medications were well tolerated.

Files

IJTPR,Vol14,Issue9,Article13.pdf

Files (385.9 kB)

Name Size Download all
md5:bf4fe23b838f70cc5d40758d01fe2545
385.9 kB Preview Download

Additional details

Identifiers

URL
http://impactfactor.org/PDF/IJTPR/14/IJTPR,Vol14,Issue9,Article13.pdf

Dates

Accepted
2024-09-27

Software

Repository URL
http://impactfactor.org/PDF/IJTPR/14/IJTPR,Vol14,Issue9,Article13.pdf

References

  • 1. Jartarkar SR, Patil A, Goldust Y, Cockerell CJ, Schwartz RA, Grabbe S, Goldust M. Pathogenesis, Immunology and Management of Dermatop hytosis. J Fungi (Basel). 2021 Dec 31;8(1):39. 2. AL-Janabi AA. Dermatophytosis: Causes, clinical features, signs, and treatment J Sympt Signs. 2014;3:200–03 3. Al Sheikh H. Epidemiology of dermatophytes in the Eastern province of Saudi Arabia. Res J Microbiol. 2009;4:229-39. 4. Kruithoff C, Gamal A, McCormick TS, Ghannoum MA. Dermatophyte Infections Worldwide: Increase in Incidence and Associated Antifungal Resistance. Life (Basel). 2023 Dec 19;14(1):1. 5. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61(1):27-37. 6. Handa S, Villasis-Keever A, Shenoy M, Anandan S, Bhrushundi M, Garodia N, Fife D, De Doncker P, Shalayda K, Hu P, Fonseca S, Cure-Bolt N. No evidence of resistance to itraconazole in a prospective real-world trial of dermatomycosis in India. PLoS One. 2023 Feb 14;18(2):e0281514. 7. Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005;1(4):299-306. 8. McKenney PT, Nessel TA, Zito PM. Antifungal Antibiotics. [Updated 2023 Mar 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/N BK538168/ 9. Maxfield L, Preuss CV, Bermudez R. Terbinafine. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/ N BK545218/ 10. Boonk W, de Geer D, de Kreek E, Remme J, van Huystee B. Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules. Mycoses. 1998;41 (1 1-12):509-14. 11. Saul A, Bonifaz A. Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. J Am Acad Dermatol. 19 90;23(3Pt 2):554-58. 12. Li RY, Wang AP, Xu JH, Xi LY, Fu MH, Zhu M, et al. Efficacy and safety of 1% terbinafine film forming solution in Chinese patients with tinea pedis: A randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Clin Drug Investig. 2014;34:223-30. 13. Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005;1(4):299-306. 14. Momin W, Vupperla D. Clinical Efficacy of Oral Terbinafine, Fluconazole and Itraconazole in the Treatment of Tinea Corporis. Asian J Res Dermatological Sci. 2018;1(1):1-10. 15. George M, Chaudhary RG, Rana D, Kasundra D, Chaudhary AR, Malhotra SD. Comparative evaluation of efficacy of terbinafine and itraconazole in the treatment of tinea cruris. Int J Basic Clin Pharmacol. 2019;8:1460-66. 16. Singh S, Chandra U, Anchan VN, Verma P, Tilak R. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole, and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial. Br J Dermatol. 2020;183(5):840-46. 17. Ellis D, Watson A. Systemic antifungal agents for cutaneous fungal infections. Aust Prescr. 1996;19(3):72–75. 18. Nozickova M, Koudelkova V, Kulikova Z, Malina L, Urbanowski S, Silny W, et al. A comparison of the efficacy of oral fluconazole, 150 mg/week versus 50 mg/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis. Int J Dermatol. 19 98;37(9):703–05. 19. Rengasamy M, Chellam J, Ganapati S. Systemic therapy of dermatophytosis: Practical and systematic approach. Clin Dermatol Rev. 2017;1(3):19–23. 20. Osborne CS, Leitner I, Hofbauer B, Fielding CA, Favre B, Ryder NS, et al. Biological, Biochemical, and Molecular Characterization of a New Clinical Trichophyton rubrum Isolate Resistant to Terbinafine. Aust Agents Chemother. 2006;50(6):2234–36. 21. Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA, et al. Clinical Trichophyton rubrum Strain Exhibiting Primary Resistance to 2003;47(1):82–86. 22. Cole GW. A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis. Arch Dermatol. 1989 ;12 5(11):1537–39. 23. Shakya NB, Jha MS, Dangol A, Shakya S, Shah A. Efficacy of itraconazole versus terbinafine for the treatment of tinea cruris. Med J Shree Birendra Hosp 2012;11:24-26. 24. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG, et al. Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: A 5-year blinded prospective follow-up study. Arch Dermatol 2002;138:353-57.